请输入关键字
确定
郝牧
研究员
研究概述
教育经历
工作经历
主持项目
代表性成果及文章

主要研究方向为浆细胞肿瘤分子发病机制,探讨多发性骨髓瘤细胞的增殖与凋亡调控机制,多发性骨髓瘤细胞与肿瘤微环境相互作用促进肿瘤免疫抑制、骨病的发病机制;探索多发性骨髓瘤等浆细胞肿瘤的生物标志物及治疗靶标。

2007年毕业于四川大学基础与法医学院医学免疫学专业,获医学博士学位;

2016.08-今  中国医学科学院血液病医院,实验血液学国家重点实验室PI,研究员

2014.01-2016.02  美国爱荷华大学多发性骨髓瘤研究中心,博士后

2011.09-2016.09  中国医学科学院血液病医院,实验血液学国家重点实验室,副研究员

2007.08-2011.08  中国医学科学院血液病医院,实验血液学国家重点实验室,助理研究员

中国医学科学院医学与健康科技创新工程重大协同创新项目,肿瘤相关骨病

国家自然科学基金面上项目 TAp73/DNp73 表达失衡在多发性骨髓瘤DNA损 伤诱导细胞凋亡中的作用及机制研究

中国医学科学院青年医学人才奖励项目 PHF19/EZH2 表观遗传学调控参与多发性骨髓瘤耐药的分子机制及逆转策略研究

1. Yu T, Du C, Ma X, Sui W, Yu Z, Liu L, Zhao L, Li Z, Xu J, Wei X, Zhou W, Deng S, Zou D, An G, Tai YT, Tricot G, Anderson KC, Qiu L, Zhan F, Hao M. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 Jul;18(7):1063-1073.

2. Li Z, Liu L, Du C, Yu Z, Yang Y, Xu J, Wei X, Zhan F, Lai Y, Qiu L, Hao M. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Ther. 2020 Jan 28. doi: 10.1038/s41417-020-0161-3. Epub ahead of print.

3: Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD Jr, Zhan F. Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia. Clin Cancer Res. 2019 Jan 1;25(1):201-209.

4: Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 Jul 2;128(7):2877-2893.

5: Qin Y, Zhang S, Deng S, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W, Chang H, Qiu L. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017 May;31(5):1123-1135.

6: Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017 Jul;31(7):1648-1650.

7. Zang M, Guo J, Liu L, Jin F, Feng X, An G, Qin X, Wu Y, Lei Q, Meng B, Zhu Y, Guan Y, Deng S, Hao M, Xu Y, Zou D, Wu M, Qiu L, Zhou W. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 2020 Mar 5;9(3):31.

8: Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X, Shang L, Tai YT, Feng X, Acharya P, Acharya C, Xu Y, Deng S, Hao M, Zou D, Zhao Y, Ru K, Qiu L, An G. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017 Mar 21;8(12):18792-18801.

9: Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F, An G, Qin Y, Sui W, Li F, Yang W, Li Z, Yi S, Zou D, Zhan F, Qiu L. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 2016 Apr 12;7(15):19589-600.

10: Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M, Qiu L. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 2015 Nov 10;6(35):38270-82.

11: Li F, Hu L, Xu Y, Li Z, Yi S, Gu Z, Li C, Hao M, Ru K, Zhan F, Zetterberg A, Yuan W, Cheng T, Qiu L. Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma. Leukemia. 2016 May;30(5):1197-201.

12: Zang M, Zou D, Yu Z, Li F, Yi S, Ai X, Qin X, Feng X, Zhou W, Xu Y, Li Z, Hao M, Sui W, Deng S, Acharya C, Zhao Y, Ru K, Qiu L, An G. Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH. Oncotarget. 2015 Oct 27;6(33):34276-87.

13: Li F, Hao M, Feng X, Zang M, Qin Y, Yi S, Li Z, Xu Y, Zhou L, Sui W, Deng S, Zou D, Zhan F, Qiu L. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res. 2015 Jul;39(7):793-9.

14: Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T, Qiu L. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget. 2015 Apr 20;6(11):9434-44.

15: An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, Yi S, Xu Y, Feng X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Anderson KC, Qiu L. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015 May 1;21(9):2148-56.

16: Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, Qi J, Li F, Hao M, Qiu L. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):286-91.

17: Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 1;75(3):594-604.

18: An G, Acharya C, Deng S, Yi S, Xu Y, Qin X, Sui W, Li Z, Shi L, Zang M, Feng X, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Tai YT, Qiu L. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Exp Hematol. 2015 Mar;43(3):168-176.e2.

19: An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, Zang M, Sui W, Yi S, Li Z, Hao M, Feng X, Jin F, Zou D, Qi J, Zhao Y, Tai YT, Wang J, Qiu L. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015 Feb;94(2):257-64.

20: Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015 Apr 15;136(8):1835-44.

21: An G, Wang H, Qin X, Shi L, Xu Y, Deng S, Sui W, Zhu G, Yao H, Yi S, Qin Y, Li F, Hao M, Ru K, Qi J, Cheng T, Wang J, Chang H, Qiu L. Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. Leuk Res. 2014 Jun;38(6):666-72.

22: Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M, Yang S, Zhao Z, Lai Y, Anderson JL, Fan J, Im HJ, Chen D, Roodman GD, Xiao G. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem. 2013 Oct 18;288(42):30399-410.

23: An G, Xu Y, Shi L, Zou D, Deng S, Sui W, Xie Z, Hao M, Chang H, Qiu L. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res. 2013 Oct;37(10):1251-7.